Zgwatinib (SOMG-833) is a potent, selective, ATP-competitive c-MET inhibitor with an IC50 of 0.93 nM against c-MET, exhibiting over 10,000-fold selectivity over 19 tyrosine kinases, including c-MET family members and highly homologous kinases; it effectively inhibits c-MET-driven cell proliferation and represents a potential candidate for the investigation of c-MET-driven human cancers.